First cohort of the Sovereign AI Fund supporting UK-based AI companies building in priority sectors.

This UKRI funding opportunity supports academically led experimental medicine studies in humans to understand the causal mechanisms of gambling disorder. It aims to deepen the understanding of how gambling activities, products, and interventions affect individuals with gambling disorder. The funding is open to researchers and academics in the UK, with no specific funding amount mentioned but typical UKRI grants can range significantly.

The UKRI Translation: MRC Impact Acceleration Awards fund research organisations to de-risk a single, high-risk development step for new medicines, medical devices, diagnostics, or other medical products. This award is for research organisations eligible for MRC funding, with grant amounts typically ranging from £50,000 to £200,000. The key requirement is to generate crucial data that significantly reduces the risk associated with a medical innovation.

The UKRI MRC proof of concept: stage two funding opportunity is for researchers employed at eligible research organizations to develop and test novel therapeutics, medical devices, diagnostics, and other interventions. This grant aims to advance early-stage research towards clinical application. Funding amounts are not explicitly stated but are expected to support significant development milestones.

This UKRI funding opportunity, previously known as the 'Developmental pathway funding scheme: stage one,' supports the development and testing of novel therapeutics, medical devices, diagnostics, and other interventions. It is open to researchers employed at eligible research organizations. The funding aims to advance early-stage medical innovations towards practical application.